Abstract
Animal scale-up is discussed as a formal approach to drug distribution in the body which permits consideration of scale through the individual processes that occur. Some of these are physical, such as blood flows, tissue binding, and kidney clearances. Others are chemical, such as metabolic reactions. The physical processes often vary quite predictably among mammalian species, and much is known about these independent of any chemical reactions. Certain metabolic reactions vary greatly and unpredictably among species. The physical and chemical processes interact so that the relationship of the pharmacokinetics of any given drug between one species and another may be quite straightforward or it may be rather obscure unless the correct interaction is perceived. Methotrexate pharmacokinetics are reviewed in discussing the use of animal scale- up for a drug where only physical processes need be considered. Problems involving metabolism are illustrated for thiopental and cytosine arabinoside.
Similar content being viewed by others
References
D. M. Himmelblau and K. B. Bischoff.Process Analysis and Simulation, Wiley, New York, 1968.
K. B. Bischoff and R. G. Brown. Drug distribution in mammals.Chem. Eng. Prog. Symp. Ser. No. 66 62: 33–45(1966).
H. L. Price, P. J. Kovnat, J. N. Safer, E. H. Conner, and M. L. Price. The uptake of thio-pental by body tissues and its relation to the duration of narcosis.Clin. Pharmacol. Therap. 1: 16–22(1960).
W. Perl, H. Rackow, E. Salanitre, G. L. Wolf, and R. M. Epstein. Intertissue diffusion effect for inert fat-soluble bases.J. Appl. Physiol. 20: 621–627 (1965).
H. Rackow, E. Salanitre, R. M. Epstein, G. L. Wolf, and W. Perl. Simultaneous uptake of N2O and cyclopropane in man as a test of compartment model.J. Appl. Physiol. 20: 611–620 (1965).
E. Krüger-Thiemer, P. Bunger, L. Dettli, P. Spring, and E. Wempe. The role of the therapeutic regimen in dosage design. I,II. Dosage regimen calculation of chemotherapeutic regimens. III. Sulfasymazine.Chemotherapia 10: 61–73, 129–144, 325–338 (1965–1966).
E. Krüger-Thiemer, W. Diller, and P. Bunger. Pharmacokinetic models regarding protein binding of drugs.Antimicrob. Agents Chemotherap., Washington, D.C., 1965, pp. 183–191 (1966).
J. R. Gillette. Reversible binding as a complication in relating thein vitro effect of drugs to theirin vivo activity. In B. B. Brodie and J. R. Gillette (eds.),Drugs and Enzymes, Vol. 4, Proc. 2nd Internat. Pharmacol. Mtg., 1963, Pergamon Press, Oxford, Czechoslovak Medical Press, Praha, 1965, pp. 9–22.
B. B. Brodie, L. C. Mark, E. M. Papper, P. A. Lief, E. Bernstein, and E. A. Rovenstine. The fate of thiopental in man and a method for its estimation in biological materials.J. Pharmacol. Exptl. Therap. 98: 85–96 (1950).
B. B. Brodie, E. Bernstein. and L. C. Mark. The role of body fat in limiting the duration of action of thiopental.J. Pharmacol. Exptl. Therap. 105: 421–426 (1952).
K. B. Bischoff, R. L. Dedrick, D. S. Zaharko, and J. A. Longstreth. Methotrexate pharma-cokinetics.J. Pharm. Sci. 60: 1128–1133 (1971).
J. Crank.The Mathematics of Diffusion, Oxford, London, 1965.
D. P. Rall. Comparative pharmacology and cerebrospinal fluid.Fed. Proc. 26: 1020–1023 (1967).
B. B. Brodie, H. Kurz, and L. S. Schanker. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid.J. Pharmacol. Exptl. Therap. 130: 20–25 (1960).
R. S. Bourke, H. L. Gabelnick, and O. Young. Mediated transport of chloride from blood into cerebrospinal fluid.Exptl. Brain Res. 10: 17–38 (1970).
H. L. Gabelnick, R. L. Dedrick, and R. S. Bourke.In vivo mass transfer of chloride during exchange hemodialysis.J. Appl. Physiol. 28: 636–640 (1970).
D. J. Reed and D. M. Woodbury. Effect of hypertonic urea on cerebrospinal fluid pressure and brain volume.J. Physiol. 164: 252–264 (1962).
K. B. Bischoff, R. L. Dedrick, and D. S. Zaharko. Preliminary model for methotrexate pharmacokinetics.J. Pharm. Sci. 59: 149–154 (1970).
R. L. Dedrick, K. B. Bischoff, and D. S. Zaharko. Interspecies correlation of plasma concentration history of methotrexate (NSC-740).Cancer Chemotherap. Rep. Pt. 1 54: 95–101 (1970).
D. S. Zaharko, R. L. Dedrick, and V. T. Oliverio. Prediction of the distribution of metho-trexate in the sting rays Dasyatidae Sabina and Sayi by use of a model developed in mice.Comp. Biochem. Physiol. 42A: 183–194 (1972).
D. S. Zaharko and V. T. Oliverio. Reinvestigation of methotrexate metabolism in rodents.Biochem. Pharmacol. 19: 2923–2924 (1970).
E. J. Freireich, E. A. Gehan, D. P. Rall, L. H. Schmidt, and H. E. Skipper. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man.Cancer Chemotherap. Rep. 50: 219–244 (1966).
E. F. Adolph. Quantitative relations in the physiological constitutions of mammals.Science 109: 579–585 (1949).
L. B. Mellett. Comparative drug metabolism.Prog. Drug. Res. 13: 136–169 (1969).
T. C. Butler. Prepared discussion. In C. O. Miller (ed.), Conference on Nonhuman Primate Toxicology, 1966, Washington, D.C., HEW, PDA, 1968, pp. 68–69.
J. G. Wagner and R. E. Damiano. Relationship among area under serum concentration curve, dose and half-life for novobiocin administered in combination with tetracycline.J. Clin. Pharmacol 8: 102–112 (1968).
K. Schmidt-Nielsen. Energy metabolism, body size, and problems of scaling.Fed. Proc. 29(4): 1524–1532 (1970).
L. C. Mark and L. Brand. Where does the pentothal go?Bull. N. Y. Acad. Med. 40: 476–482 (1964).
L. J. Saidman and E. I. Eger. The effect of thiopental metabolism on duration of anesthesia.Anesthesiology 27: 118–126 (1966).
K. B. Bischoff and R. L. Dedrick. Thiopental pharmacokinetics.J. Pharm. Sci. 57: 1346–1357 (1968).
G. W. Camiener and C. G. Smith. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.Biochem. Pharmacol. 14: 1405–1416 (1965).
G. W. Camiener. Studies of the enzymatic deamination of cytosine arabinoside. II. Properties of the deaminase of human liver.Biochem. Pharmacol. 16: 1681–1689 (1967).
G. W. Camiener. Studies of the enzymatic deamination of cytosine arabinoside. III. Substrate requirements and inhibitors of the deaminase of human liver.Biochem. Pharmacol. 16: 1691–1702 (1967).
R. V. Loo, M. J. Brennan, and R. W. Talley. Clinical pharmacology of cytosine arabinoside.Proc. Am. Ass. Cancer Res. 6: 41 (1965).
L. T. Mulligan and L. B. Mellett. A useful thin-layer chromatography method for the determination of cytidine aminohydrolase activity in serum.J. Chromatog. 43: 376–381 (1969).
R. Tomchick, L. D. Saslaw. and V. S. Waravdekar. Mouse kidney cytidine deaminase purification and properties.J. Biol. Chem. 243: 2534–2537 (1968).
R. L. Dedrick. D. D. Forrester, and D. H. W. Ho.In vitro-in vivo correlation of drug metabolism—Deamination of 1-β-d-arabinofuranosylcytosine.Biochem. Pharmacol. 21: 1–16 (1972).
A. Reinberg and F. Halberg. Circadian chronopharmacology.Ann. Rev. Pharmacol. 11: 455–492 (1971).
E. Haus, F. Halberg, L. E. Scheving, J. E. Pauly, S. Cardosa, J. F. W. Kuhl, R. B. Sothern, R. N. Shiotsuka, and D. S. Hwang. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system.Science 177: 80–82 (1972).
J. G. Wagner. Pharmacokinetics.Ann. Rev. Pharmacol. 8: 67–94 (1968).
J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971.
K. B. Bischoff, K. J. Himmelstein, R. L. Dedrick, and D. S. Zaharko. InAdvances in Chemistry Series No. 118, American Chemical Society, Washington, D.C., 1973, pp. 47–64.
B. B. Brodie and W. D. Reid. Some pharmacological consequences of species variation in rate of metabolism.Fed. Proc. 26: 1062–1070 (1967).
W. C. Werkheiser. Mathematical simulation in chemotherapy.Ann. N.Y. Acad. Sci. 186: 343–358 (1971).
D. S. Zaharko and R. L. Dedrick, Applications of pharmacokinetics to cancer chemotherapy.Pharmacology and the Future of Man. Proc. 5th Internat. Congr. Pharmacol., Vol. 3, Karger, Basel, 1973, pp. 316–331.
D. L. Mount and H. W. Boyle. Parathion—Use of blood concentration to diagnose mortality of fish.Environ. Sci. Tech. 3: 1183–1185 (1969).
R. L. Dedrick, P. Vantoch, E. A. Gombos, and R. Moore. Kinetics of activated carbon kidney.Trans. Am. Soc. Artif. Int. Organs 13: 236–242 (1967).
R. L. Dedrick, D. S. Zaharko, and R. J. Lutz. Transport and binding of methotrexatein vivo.J. Pharm. Sci. 62: 882–890 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dedrick, R.L. Animal scale-up. Journal of Pharmacokinetics and Biopharmaceutics 1, 435–461 (1973). https://doi.org/10.1007/BF01059667
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059667